newsfilter
← Latest News
GlobeNewswire·

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

  • BioAge Labs dosed the first participant in September 2026 in the Phase 2 QUELL-DME trial for BGE-102 in diabetic macular edema, with topline results expected in the second half of 2027.
  • The Phase 2 dose-ranging QUELL-CV trial for BGE-102 in adults with obesity & elevated inflammation completed enrollment of approximately 160 participants, with topline data anticipated in the fourth quarter of 2026.
  • The APJ agonist program for obesity remains on track for an IND submission by the end of 2026.
  • Collaboration revenue for Q3 2026 was $0.3 million, a decrease from $2.1 million in 2025 due to a Novartis agreement amendment catch-up adjustment.
  • R&D expenses rose to $30.2 million in Q3 2026 from $18.5 million in 2025, driven by increased clinical trial & manufacturing costs for BGE-102.
  • Net loss for Q3 2026 was $33.5 million, or $0.73 per share, compared to $20.2 million, or $0.56 per share, in the same period in 2025.
  • As of September 30, 2026, BioAge held approximately $352.3 million in cash & equivalents, sufficient to fund operations through 2029.
  • BioAge reached its first milestone with Deep Origin in October 2026, validating computationally identified hits against a novel target for advancement.